Neoadjuvant chemotherapy equalizes the optimal cytoreduction rate to primary surgery without improving survival in advanced ovarian cancer.

---

Taşkın S., Gungor M. , Ortac F., Öztuna D.

Archives of gynecology and obstetrics, vol.288, pp.1399-403, 2013 (Journal Indexed in SCI)

• Publication Type: Article / Article
• Volume: 288
• Publication Date: 2013
• Doi Number: 10.1007/s00404-013-2924-7
• Title of Journal : Archives of gynecology and obstetrics
• Page Numbers: pp.1399-403

Abstract

To evaluate results of neoadjuvant chemotherapy (NACT) following debulking surgery in patients with extensive metastatic disease and/or poor medical performance